Article Information
- Received August 9, 2019
- Revision received August 19, 2019
- Accepted August 22, 2019
- Published online August 26, 2019.
Author Information
Author contributions
Author contributions: H.E.S., M.K., Z.X., and C.M.P. designed research; H.E.S., M.K., Z.X., S.L., and A.D. performed research; H.E.S., M.K., and C.M.P. analyzed data; H.E.S. and C.M.P. wrote the paper; C.M.P. contributed unpublished reagents/analytic tools.
↵* H.E.S. and M.K. contributed equally to this work.
Disclosures
The authors declare no competing financial interests.
This work was supported by United States Department of Health and Human Services National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development Grants R01HD069560 and R01HD069560-S1 (to C.M.P.), Autism Speaks (Autism Speaks Inc.) Grants (to C.M.P), Autism Speaks Grants (7666 to C.M.P, 7898 to H.E.S.) Autism Science Foundation Pre-doctoral Fellowship (to C.O.E.), The Hartwell Foundation (C.M.P.), Ed and Sue Rose Distinguished Professorship in Neurology (C.M.P.), BRAINS for Autism (C.M.P.), Virginia B. Spencer Endowed Chair at UAB (C.M.P.), and Dr. Clay Heighten and Dr. Debra Caudy (C.M.P.). C.M.P. has accepted travel funds and honoraria to speak once at each of the following companies: Psychogenics, Inc.; Astra-Zeneca; Roche; Pfizer; and Dainippon Sumitomo Pharma Co. C.M.P. also has investigator-initiated grant funding for clinical research with Novartis.
Funding
HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
R01HD069560; R01HD069560-S1Autism Speaks (Autism Speaks Inc.)
Autism Science Foundation (ASF)
The Hartwell Foundation
Ed & Sue Rose Distinguished Professorship in Neurology
BRAINS for Autism
Drs. Clay Heighten and Debra Caudy
Other Version
- You are viewing the most recent version of this article.
- previous version (August 26, 2019).
Article usage
In this issue
